» Articles » PMID: 33208941

Defining HPV-specific B Cell Responses in Patients with Head and Neck Cancer

Overview
Journal Nature
Specialty Science
Date 2020 Nov 19
PMID 33208941
Citations 100
Authors
Affiliations
Soon will be listed here.
Abstract

Tumours often contain B cells and plasma cells but the antigen specificity of these intratumoral B cells is not well understood. Here we show that human papillomavirus (HPV)-specific B cell responses are detectable in samples from patients with HPV-positive head and neck cancers, with active production of HPV-specific IgG antibodies in situ. HPV-specific antibody secreting cells (ASCs) were present in the tumour microenvironment, with minimal bystander recruitment of influenza-specific cells, suggesting a localized and antigen-specific ASC response. HPV-specific ASC responses correlated with titres of plasma IgG and were directed against the HPV proteins E2, E6 and E7, with the most dominant response against E2. Using intratumoral B cells and plasma cells, we generated several HPV-specific human monoclonal antibodies, which exhibited a high degree of somatic hypermutation, consistent with chronic antigen exposure. Single-cell RNA sequencing analyses detected activated B cells, germinal centre B cells and ASCs within the tumour microenvironment. Compared with the tumour parenchyma, B cells and ASCs were preferentially localized in the tumour stroma, with well-formed clusters of activated B cells indicating ongoing germinal centre reactions. Overall, we show that antigen-specific activated and germinal centre B cells as well as plasma cells can be found in the tumour microenvironment. Our findings provide a better understanding of humoral immune responses in human cancer and suggest that tumour-infiltrating B cells could be harnessed for the development of therapeutic agents.

Citing Articles

Tumor-infiltrating and circulating B cells mediate local and systemic immunomodulatory mechanisms in Glioblastoma.

De Domenico P, Gagliardi F, Roncelli F, Snider S, Mortini P J Neurooncol. 2025; .

PMID: 40080248 DOI: 10.1007/s11060-025-04989-z.


Tumor-infiltrating B cells in non-small cell lung cancer: current insights and future directions.

Jiang S, Zhu D, Wang Y Cancer Cell Int. 2025; 25(1):68.

PMID: 40011889 PMC: 11866835. DOI: 10.1186/s12935-025-03668-3.


A tumor-binding antibody with cross-reactivity to viral antigens.

Campa M, Gottlin E, Wiehe K, Patz Jr E Cancer Immunol Immunother. 2025; 74(4):126.

PMID: 40009215 PMC: 11865367. DOI: 10.1007/s00262-025-03975-8.


Distinct maturity and spatial distribution of tertiary lymphoid structures in head and neck squamous cell carcinoma: implications for tumor immunity and clinical outcomes.

Xu S, Han C, Zhou J, Yang D, Dong H, Zhang Y Cancer Immunol Immunother. 2025; 74(3):107.

PMID: 39932546 PMC: 11813844. DOI: 10.1007/s00262-025-03952-1.


B cells in non-lymphoid tissues.

Samiea A, Celis G, Yadav R, Rodda L, Moreau J Nat Rev Immunol. 2025; .

PMID: 39910240 DOI: 10.1038/s41577-025-01137-6.


References
1.
Cabrita R, Lauss M, Sanna A, Donia M, Skaarup Larsen M, Mitra S . Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature. 2020; 577(7791):561-565. DOI: 10.1038/s41586-019-1914-8. View

2.
Helmink B, Reddy S, Gao J, Zhang S, Basar R, Thakur R . B cells and tertiary lymphoid structures promote immunotherapy response. Nature. 2020; 577(7791):549-555. PMC: 8762581. DOI: 10.1038/s41586-019-1922-8. View

3.
Petitprez F, De Reynies A, Keung E, Chen T, Sun C, Calderaro J . B cells are associated with survival and immunotherapy response in sarcoma. Nature. 2020; 577(7791):556-560. DOI: 10.1038/s41586-019-1906-8. View

4.
Flynn N, Somasundaram R, Arnold K, Sims-Mourtada J . The Multifaceted Roles of B Cells in Solid Tumors: Emerging Treatment Opportunities. Target Oncol. 2017; 12(2):139-152. DOI: 10.1007/s11523-017-0481-x. View

5.
Yuen G, Demissie E, Pillai S . B lymphocytes and cancer: a love-hate relationship. Trends Cancer. 2017; 2(12):747-757. PMC: 5472356. DOI: 10.1016/j.trecan.2016.10.010. View